Washington, DC 20006-5349
HELPLINE
Today, the Meso Foundation wrote a letter to the acting administrator of the EPA urging the agency to account for legacy asbestos when evaluating asbestos risk and the magnitude of the asbestos problem. This letter came as a response to the EPA’s decision to exclude legacy uses of asbestos in its problem formulation. This issue is separate from the recently publicized ‘significant new use rule.’ You can read more here.
EPA_Legacy_Comment_MesoFoundation
Peritoneal mesothelioma patients have a few different treatment options available. This session discusses two options: surgery as well as hyperthermic intraperitoneal chemotherapy (HIPEC). This session
A mesothelioma diagnosis and recurrence monitoring has many facets. Patients, when seeing their oncologists, may hear information about imaging, biopsies, pathology, and biomarkers and genetic
These sessions showcase case studies over dual compartment disease and immunotherapy vs. chemotherapy. These sessions are presented by:R. Taylor Ripley, MD, Baylor College of MedicineManish
Get the latest information about mesothelioma, clinical trials, patient stories, community events, and much more!
